Displaying drugs 4426 - 4450 of 5183 in total
Chiglitazar
Chiglitazar is under investigation in clinical trial NCT06125587 (Chiglitazar/metformin in Non-obese Women With PCOS).
Investigational
Daclizumab
Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences...
Investigational
Withdrawn
Matched Description: … Despite being approved for use, Zinbryta (daclizumab)'s complex pre-existing safety profile consisting …
Fluorocyclopentenylcytosine
Fluorocyclopentenylcytosine is under investigation in clinical trial NCT03189914 (RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer).
Investigational
LX6171
LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia.
Investigational
Bevirimat
Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. This compound belongs to the androgens and derivatives, which are hydroxylated C19 steroid hormones. They are known to favour the development of masculine characteristics. They also show profound effects on...
Investigational
Matched Description: … Bevirimat targets the protein gag-pol polyprotein. …
WSD-0922
Investigational
Aspartame
Flavoring agent sweeter than sugar, metabolized as phenylalanine and aspartic acid.
Investigational
Nutraceutical
3-Fluoro-2-Methyl-Aniline
Experimental
Farletuzumab ecteribulin
Farletuzumab ecteribulin is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of Morab-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (Frα)-targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types).
Investigational
Alferminogene tadenovec
Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease. Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration...
Investigational
Oseltamivir acid
Experimental
Fostroxacitabine bralpamide
Investigational
Pixofisiran
Investigational
o-Cymen-5-ol
Experimental
Icotinib
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the...
Experimental
Investigational
Matched Categories: … Protein Kinase Inhibitors …
Echinacoside
Echinacoside is a phenylethanoid glycoside isolated from Echinacea angustifolia in 1950, and currently being investigated for the treatment of Parkinson's, Alzheimer's, atherosclerosis, osteoporosis, acute colitis, wound treatment, and hepatitis. Echinacoside has demonstrated inhibition of apoptosis in neural cell lines, demonstrating potential for use in the treatment of neurological conditions.
Experimental
Ceftiofur
Ceftiofur is a third generation cephalosporin antibiotic, first described in 1987, and now used in veterinary medicine. It is marketed by pharmaceutical company Zoetis as Excenel, and is the active ingredient in that company's Specramast LC (lactating cow formula) product. It is resistant to hydrolysis by beta-lactamase, and has activity...
Vet approved
CAM-101
CAM-101 is an allogeneic human platelet lysate product depleted of fibrinogen.
Investigational
Batroxobin
Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. The...
Experimental
Matched Description: … Recombinant Batroxobin in relatively affordable and could be accessed by mass production. …
Sophora flavescens root
Experimental
STX-107
Investigational
Human blood group H type 1 trisaccharide
Experimental
Befiradol
Befiradol is under investigation in clinical trial NCT05148884 (Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia).
Investigational
Displaying drugs 4426 - 4450 of 5183 in total